Humuline Nph Cartridge (Insulin Human (Rdna))

Humuline NPH Cartridge is indicated for the long‑term management of blood glucose in adults and children with diabetes.

• As part of a basal insulin regimen for type 1 diabetes mellitus, providing steady insulin levels between meals and overnight.
• In combination with rapid‑acting insulin analogues for intensive insulin therapy in type 2 diabetes mellitus.
• To replace or supplement endogenous insulin in patients with pancreatic insufficiency or after pancreatectomy.
• For use in insulin‑treated patients who require a predictable intermediate‑acting insulin profile.
• As a component of a structured diabetes self‑management plan under medical supervision.

• Humuline NPH contains recombinant human insulin that binds to the insulin receptor on cell membranes. Receptor activation triggers autophosphorylation of the β‑subunit, initiating the intracellular PI3‑kinase/Akt pathway. This cascade promotes translocation of GLUT‑4 transporters to the plasma membrane, increasing glucose uptake in muscle and adipose tissue, while also inhibiting hepatic gluconeogenesis. The intermediate‑acting formulation releases insulin gradually, providing a prolonged basal effect.

Adverse reactions to Humuline NPH Cartridge may vary in frequency and severity.

Common

• Mild to moderate hypoglycemia, especially if meals are delayed, carbohydrate intake is reduced, or physical activity is increased.
• Localized redness, swelling, tenderness, or itching at the injection site, usually resolving within a few days.
• Lipodystrophy presenting as small lumps, thickened skin, or indentations under the skin at repeated injection sites.
• Transient weight gain, often modest, associated with improved glycemic control and fluid retention.

Serious

• Severe hypoglycemia with neuroglycopenic symptoms such as confusion, visual disturbances, seizures, or loss of consciousness.
• Allergic reactions ranging from mild urticaria and rash to life‑threatening anaphylaxis, requiring immediate medical attention.
• Persistent peripheral edema or worsening heart failure symptoms in patients with pre‑existing cardiac disease.

When prescribing Humuline NPH Cartridge, clinicians should consider several precautionary measures to ensure safe use.

• Assess renal and hepatic function, as impairment may alter insulin clearance and increase hypoglycemia risk.
• Monitor blood glucose closely during initiation, dose adjustments, and periods of illness or stress.
• Educate patients on proper injection technique and rotation of sites to minimize lipodystrophy.
• Use caution in pregnant or breastfeeding women; benefits should be weighed against potential risks.
• Review concomitant medications that can potentiate hypoglycemia, such as sulfonylureas or meglitinides.
• Advise patients to carry rapid‑acting glucose sources in case of unexpected hypoglycemia.

Humuline NPH Cartridge can interact with other agents that affect blood glucose or insulin metabolism.

Avoid

• Concurrent use of other insulin products or high‑dose sulfonylureas, which may cause severe hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms, making detection more difficult.

Use with caution

• Corticosteroids, which can increase insulin resistance and require dose adjustments.
• Thiazide diuretics, which may raise blood glucose levels.
• Alcohol consumption, especially in excess, as it can cause unpredictable glucose fluctuations.
• ACE inhibitors or ARBs, which generally have minimal effect but may require monitoring of renal function and glucose.
• Beta‑agonists (e.g., albuterol) used for asthma, which can transiently raise blood glucose.